first booster dose for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 prophylaxis (excluding children) meta-analysis
C4591031- first boost NCT04955626		RCT	first booster dose	Comirnaty (tozinameran - Pfizer/BIONTECH)	COVID-19 prophylaxis (excluding children)	low	5081/5044	conclusif	demonstrated 95 % decrease in confirmed COVID (any severity) (PE) with a high degree of certainty due to low risk of bias
C4591031- first boost NCT04955626		RCT	first booster dose	complete primary vaccine series	COVID-19 prophylaxis (excluding children)	low	5081/5044	conclusif	demonstrated 95 % decrease in confirmed COVID (any severity) (PE) with a high degree of certainty due to low risk of bias
32 studies excluded by filtering options (2 RCT / 30 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 prophylaxis (excluding children) meta-analysis